PNAG vaccine

**PNAG vaccine** is a conjugate vaccine targeting the conserved microbial surface polysaccharide **poly-β-(1–6)-N-acetylglucosamine (PNAG)**, expressed by over 90% of tested bacterial, fungal, and protozoal pathogens including *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Acinetobacter baumannii*, and others. It elicits opsonic antibodies that promote complement-mediated killing and phagocytosis, with deacetylated or partially N-acetylated PNAG variants (e.g., 40-50% acetylation, chain lengths of 8-12 mers) showing optimal immunogenicity in preclinical models. Developed primarily by **Alopexx** as **AV0328** (synthetic PNAG conjugated to tetanus toxoid), it completed **Phase 1** trials (NCT02853617) demonstrating safety, tolerability, and functional antibodies against PNAG-expressing pathogens; it targets invasive diseases like pneumococcal infections not covered by serotype-specific vaccines, with broad-spectrum potential against antibiotic-resistant and biofilm-associated infections.[1][2][3][5]

Brand names

AV0328AV-0328AV 0328

Other names

poly-N-acetylglucosamine vaccinepoly-β-(1–6)-N-acetyl-D-glucosamine vaccinedPNAG vaccine5GlcNH2–TT